Metsera Inc. (MTSR)
NASDAQ: MTSR
· Real-Time Price · USD
23.30
3.49 (17.62%)
At close: Apr 29, 2025, 3:59 PM
24.57
5.45%
After-hours: Apr 29, 2025, 07:04 PM EDT
Company Description
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases.
It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity.
The company was incorporated in 2022 and is headquartered in New York, New York.
Metsera Inc.
| Country | United States |
| IPO Date | Jan 31, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 74 |
| CEO | Christopher Whitten Bernard |
Contact Details
Address: 3 World Trade Center New York, New York United States | |
| Website | https://metsera.com |
Stock Details
| Ticker Symbol | MTSR |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0002040807 |
| CUSIP Number | n/a |
| ISIN Number | US59267L1070 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Christopher Whitten Bernard | Co-Founder, President, Chief Executive Officer & Director |
| Christopher J. Visioli | Co-Founder, Chief Financial Officer & Chief Business Officer |
| Christopher Todd Cox | Chief Legal Officer |
| Daniel Hoey | Chief Technical Operations Officer |
| Dr. Brian Hubbard Ph.D. | Chief Scientific Officer |
| Dr. Clive A. Meanwell M.D., Ph.D. | Co-Founder & Executive Chairman |
| Dr. Gbolahan Amusa Benz C.F.A., M.D. | EVice President of Strategic Finance & Investor Relations |
| Michael Donovan | Chief Design Officer |
| Nancye Green | Chief Experience Officer |
| Paul L. Berns | Co-Founder & Lead Independent Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2025 | 8-K | Current Report |
| Jan 31, 2025 | SEC STAFF LETTER | Filing |
| Jan 28, 2025 | CORRESP | Filing |
| Jan 28, 2025 | CORRESP | Filing |
| Jan 28, 2025 | CORRESP | Filing |
| Jan 27, 2025 | CORRESP | Filing |
| Jan 21, 2025 | UPLOAD | Filing |
| Jan 10, 2025 | CORRESP | Filing |
| Dec 26, 2024 | SEC STAFF LETTER | Filing |
| Dec 26, 2024 | UPLOAD | Filing |